Overview of Viread

Property	Description
Active Ingredient	Tenofovir Disoproxil Fumarate (TDF)
Form	Oral Film-coated tablet, Oral powder
Pharmacological Class	Nucleotide Reverse Transcriptase Inhibitor (NRTI)
Origin	Synthetic Prodrug
Therapeutic Role	Viral Suppression

What Type of Medicine is Tenofovir Disoproxil Fumarate?

Tenofovir Disoproxil Fumarate (TDF) is a synthetic, orally administered prescription medicine classified as an antiretroviral agent. It is formally designated as a Nucleotide Reverse Transcriptase Inhibitor (NRTI), a class of drugs that directly interferes with the replication cycles of specific viruses. The compound is chemically an acyclic nucleoside phosphonate analog. This unique molecular structure is a differentiating factor, as TDF is a nucleotide analog, leading to distinct cellular processing and pharmacological properties compared to older nucleoside inhibitors.

Composition and Available Form

The medication is formulated as a single-entity product containing Tenofovir Disoproxil Fumarate, which functions as a pharmacologically inactive precursor known as a prodrug. This design is critical for ensuring efficient absorption after the medicine is taken orally as a film-coated tablet or oral powder. The TDF molecule must be converted inside the body's cells to the active compound, tenofovir diphosphate, which is the molecule that performs the direct antiviral work. The solid forms are composed of the active crystalline powder alongside essential inactive pharmaceutical excipients, suitable for oral use.

General Therapeutic Role and Purpose

The primary purpose of this medicine is to achieve sustained viral suppression by selectively blocking key viral enzymes. Antiretrovirals like TDF are fundamental to treatment strategies for managing chronic viral conditions. This means the medication helps control the disease by reducing the overall amount of virus circulating in the body. This approach has been clinically recognized worldwide as a cornerstone of essential medicine, validating its role in controlling long-term viral load in eligible patients.

What side effects are possible with Viread?

Safety Information and Adverse Reactions

Serious and Clinically Significant Adverse Reactions

The most serious warnings associated with Viread (tenofovir disoproxil fumarate) include the risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis (enlarged liver with fat accumulation), which may include fatal cases and are a known class effect of nucleoside analogs.

In patients co-infected with Hepatitis B Virus (HBV), severe acute exacerbations of hepatitis B have been reported upon discontinuation of Viread, requiring close clinical and laboratory monitoring of hepatic function for several months after stopping the medication.

Organ-System Specific Risks

Kidney (Renal) Toxicity: New onset or worsening renal impairment, including acute renal failure and Fanconi Syndrome, has been documented. Renal function monitoring (creatinine clearance, serum phosphorus, urine glucose, urine protein) is mandatory before starting and periodically during treatment, and coadministration with nephrotoxic drugs should be avoided.
Bone Effects: Decreases in Bone Mineral Density (BMD) have been observed, leading to reports of osteomalacia (softening of the bone) and related fractures in some patients, sometimes linked to proximal renal tubulopathy.
Immune System: In HIV-infected individuals, Immune Reconstitution Inflammatory Syndrome (IRIS) has been reported following the initiation of combination antiretroviral therapy.

Common Adverse Reactions

The most frequently reported side effects (incidence ge 10% in some adult populations) involve the gastrointestinal system and the nervous system. These include diarrhea, nausea, headache, asthenia (weakness), and rash.

Restrictions

Viread should not be administered concurrently with other tenofovir-containing products (such as ATRIPLA, COMPLERA, or TRUVADA). For HIV-infected patients, this medication must be used only as part of an appropriate combination antiretroviral regimen.

Overdose and Emergency Response

Overdose and when to seek help

This information summarizes the official regulatory statements regarding overdose with Tenofovir Disoproxil Fumarate (Viread).

Acute Manifestations and Severity

Clinical experience indicates that doses up to 600 mg per day—which is double the maximum recommended daily dose—did not result in serious acute adverse effects. No specific acute manifestations or life-threatening symptoms are detailed in the official regulatory overdose sections for a single, acute event. The management framework is therefore based on the principle of supportive care rather than a documented acute symptom profile. No specific antidote is known to be available.

Emergency Action and Management Protocol

Seek immediate medical attention for any suspected overdose. It is officially mandated to contact a healthcare provider or a poison control center immediately, or to proceed to the nearest hospital emergency department.

Treatment following an overdose must consist of providing standard supportive measures and symptomatic treatment. The patient must be monitored closely for any signs of toxicity. While a specific antidote does not exist, the active component, tenofovir, is known to be efficiently removed from the body using hemodialysis, a procedure that may be utilized in severe cases.

The official overdose documentation provides no specific population-based considerations (e.g., pediatric or geriatric) unique to acute overdose scenarios.

Therapeutic Uses of Viread

Quick Facts: Viread (Tenofovir Disoproxil Fumarate)

Chronic Hepatitis B: May assist in managing the effects of chronic hepatitis B virus (HBV) infection in adults and pediatric patients.
HIV-1 Infection: Used in combination with other antiretroviral agents for the management of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and in certain pediatric populations.

What Viread Treats: Main Uses and Benefits

Viread (tenofovir disoproxil fumarate) is a prescription antiviral medication indicated for the management of specific viral infections. The medication is used to help control the progression of chronic Hepatitis B (HBV) infection. This usage is applicable to both adults and pediatric patients weighing at least 10 kg.

Additionally, Viread is used as a component of a comprehensive regimen for managing Human Immunodeficiency Virus type 1 (HIV-1) infection. When utilized in combination with other antiretroviral agents, the drug assists in reducing the level of the HIV-1 virus in the blood, which may support immune function. This may help in the overall management of the condition and is approved for use in adults and pediatric patients aged 2 years and older who weigh at least 10 kg.

The use of this medication is established in these therapeutic domains. The appropriate use of this medication in a combination regimen may assist individuals in controlling viral activity associated with HIV-1 and HBV infections.

Eligibility and Restrictions for Use

Viread (tenofovir disoproxil fumarate) eligibility is determined by specific regulatory criteria regarding age, weight, co-existing conditions, and organ function, as defined in official prescribing information.

Contraindicated and Prohibited Populations

The medicine is contraindicated in patients with a known hypersensitivity to the active substance or its excipients. Co-administration is prohibited with any other products containing tenofovir disoproxil fumarate (e.g., ATRIPLA, COMPLERA, or TRUVADA).

Eligibility by Age and Condition

Viread is approved for adults. For pediatric use, it is approved for children 2 years of age and older who weigh at least 10 kg. Use in children under 2 years of age is not established.

Eligibility is restricted by renal function. For adults, the dosing interval requires adjustment if Creatinine Clearance (CrCl) is below 50 mL/min. The medicine is not recommended for pediatric patients with existing renal impairment or any patients with severe renal impairment (CrCl < 30 mL/min). No dosing recommendation is available for patients with CrCl < 10 mL/min who are not undergoing hemodialysis.

Special Populations Status

Pregnancy status involves enrollment in a dedicated registry for monitoring. HIV-infected mothers taking this medicine must not breastfeed to prevent the risk of HIV transmission. Insufficient data exist to make specific dose recommendations for patients over 65 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official regulatory profile for Viread focuses on interactions related to renal clearance, additive organ toxicity, and systemic exposure modification.

Medicinal product categories with documented interactions: Nephrotoxic Agents, HIV-1 Protease Inhibitors (especially boosted regimens), Nucleotide/Nucleoside Analogues, Renal Transporter Competitors, and Gastrointestinal Absorbents.
Specific interacting medicines (if explicitly listed): Adefovir Dipivoxil, Didanosine, Atazanavir, Ritonavir or Cobicistat (as boosters), and other Tenofovir-containing products.

Interaction Classifications (High-Level)

Interaction severity classification: Combinations are classified as Prohibited (Adefovir, therapeutic duplicates), Not Recommended (Didanosine), or requiring Use with Caution/Avoidance (Nephrotoxic Agents).
Mechanistic basis of interactions: The active drug is eliminated by active tubular secretion via renal transporters; competing drugs may increase its plasma concentrations. Other interactions involve additive nephrotoxicity and pharmacokinetic effects on co-administered agents.
Population-specific interaction notes: The risk of interaction-associated renal impairment is heightened in patients with renal risk factors or low body weight when co-administered with nephrotoxic drugs or boosted Protease Inhibitors.

Official Interaction Statements

Co-administration with Adefovir Dipivoxil and other Tenofovir-containing products is prohibited due to toxicity and therapeutic duplication.
The combination with Didanosine is not recommended because it increases Didanosine systemic exposure by 40-60%.
Co-administration with nephrotoxic drugs must be avoided due to the officially documented additive risk of renal impairment.
Atazanavir must be used with Ritonavir when taken with Viread to prevent a decrease in Atazanavir concentration.
Lopinavir/Ritonavir co-administration also officially increases tenofovir concentrations, supporting the need for monitoring with any boosted Protease Inhibitor.
Activated Charcoal requires a 4-hour separation from Viread administration to prevent reduced absorption.

Mechanism of Action

Intracellular Activation and Substrate Mimicry

Viread (tenofovir disoproxil fumarate) is a prodrug that must first undergo a two-step intracellular phosphorylation process within host cells to become the active metabolite, tenofovir diphosphate ( TFV-DP). This metabolite serves as a false building block, or substrate mimic, structurally similar to a natural deoxyadenosine triphosphate.

Enzyme Inhibition and DNA Chain Termination

The TFV-DP targets and functions as a competitive inhibitor of the viral enzyme Reverse Transcriptase (for HIV) or DNA Polymerase (for HBV). When the active metabolite is incorporated into the growing viral DNA chain, it lacks the necessary 3'-hydroxyl group required for further chain elongation. This action results in the immediate and irreversible termination of viral DNA synthesis, halting the replication process.

Modulating Viral Proliferation and Particle Count

This molecular arrest of DNA synthesis is the key step that restricts the ability of the virus to generate new genetic material and subsequently multiply. As a physiological consequence of this terminated replication cycle, there is a reduction in the concentration of circulating viral particles due to the sustained limitation of viral proliferative capacity.

Dosage and Administration Information

How Viread is Used

The administration of Viread (tenofovir disoproxil fumarate) follows standardized, official prescribing protocols that govern the route, frequency, and dosage adjustments required for proper use. The medication is delivered via the oral route, available primarily as a 300 mg film-coated tablet for adults and also as an oral powder and lower-strength tablets for pediatric use.

Standard Administration and Timing

For adults with normal kidney function, the established regimen is 300 mg taken once daily. The official instructions specify that the 300 mg film-coated tablets can be administered without regard to food, while the oral powder must be taken with food. Guidance for a missed dose specifies that if the lapse is less than 12 hours from the scheduled time, the dose should be taken, but if it is greater than 12 hours, the missed dose should be skipped.

Population-Specific Procedural Rules

An essential procedural requirement is the modification of the dosing interval for individuals with reduced kidney function. For patients with creatinine clearance (CrCl) below 50 mL/min, the official instructions mandate extending the interval between doses (e.g., 300 mg every 48 hours or longer) to control systemic exposure. Pediatric dosing is based on body weight, with children receiving 8 mg/kg up to the adult maximum of 300 mg. Furthermore, the use protocol strictly prohibits its co-administration with any other medicinal product containing tenofovir disoproxil fumarate or tenofovir alafenamide, which prevents an excessive dose of the active substance.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Viread (tenofovir disoproxil fumarate or TDF) is an antiviral medication indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, and for the treatment of chronic hepatitis B virus (HBV) infection.

Findings in Chronic Hepatitis B

Clinical trials, including pivotal Phase III studies, have evaluated TDF for the treatment of chronic HBV, focusing on viral suppression and long-term outcomes. Research consistently suggests TDF is associated with durable suppression of HBV DNA levels in the blood. Studies examining treatment over four to five years reported sustained viral load suppression in the majority of participants. Notably, these long-term studies indicated a high barrier to resistance, with no development of drug resistance reported among study participants over five years of treatment.

Further research analyzed the effect of TDF on liver health over five years. Findings suggested an association with a reduction in measures of liver fibrosis and the reversal of cirrhosis in a significant proportion of patients who had paired liver biopsies. This indicated a potential for improvement in overall liver histology with long-term therapy.

Safety Profile Considerations

Comparative and long-term studies have extensively characterized the safety profile. Data from various trials and post-marketing surveillance show that renal events, including mild to moderate elevations in serum creatinine and, rarely, severe acute kidney injury, have been reported in association with TDF use. Additionally, decreases in bone mineral density (BMD) at the hip and spine have been observed. Risk factors for these effects often include advanced age, low body weight, and pre-existing renal issues. The most commonly reported adverse events generally involve mild gastrointestinal symptoms, such as nausea and diarrhea.

Frequently Asked Questions (FAQ)

Common questions about Viread (FAQ)

Q: Do I need to take Viread with food, or can I take it on an empty stomach?

A: According to the official product information, the film-coated tablets can be administered without regard to food, meaning they can be taken on an empty or full stomach. However, the oral powder formulation is directed to be taken with food to ensure proper absorption into the body.

Q: Is it true that Viread is sometimes used to prevent illness?

A: The active ingredient in Viread, tenofovir disoproxil fumarate, is a component used in combination medicines that are indicated for use in pre-exposure prophylaxis (PrEP). PrEP is a prevention method described as helping to reduce the risk of sexually acquired HIV-1 infection, based on official documentation for certain formulations containing the drug.

Q: Is Viread appropriate for use during pregnancy, based on official information?

A: Official data from human pregnancy registries have shown no association between maternal use of the drug and birth defects in the offspring. The drug's use during pregnancy is addressed in regulatory documents, with the decision to use it being determined by a healthcare provider when the potential benefit is determined to outweigh the potential risk.

Q: Is the long-term safety profile of Viread well-documented?

A: The long-term safety profile has been extensively characterized by data collected from clinical trials and ongoing post-marketing surveillance. This documentation helps define potential long-term effects, such as decreases in bone mineral density (BMD) and possible renal (kidney) events, which are subject to monitoring.

Q: Does Viread cause weight gain or weight loss?

A: While weight gain is not typically listed as a common or specific adverse reaction, official documents mention weight loss in some post-marketing data. Additionally, changes in the shape or location of body fat, known as lipodystrophy, have been reported as a possible effect.

Q: Is it common to feel tired when first starting Viread?

A: Official drug labels list asthenia as a frequently reported side effect. Asthenia is the medical term for a feeling of weakness or lack of energy, which is often described as tiredness.

Q: Is Viread used to treat any conditions besides HIV?

A: According to the official indication section, Viread is used for the treatment of HIV-1 infection in combination with other agents. It is also indicated for the treatment of chronic hepatitis B virus (HBV) infection.

Q: What happens if I miss a dose of Viread?

A: Guidelines from authoritative bodies describe that if the lapse in a dose is less than 12 hours from the scheduled time, the dose should be taken. If greater than 12 hours have passed since the scheduled time, the missed dose should be skipped, and the regular schedule should be maintained.

Q: What is the difference between Viread and other tenofovir formulations?

A: Viread contains the prodrug tenofovir disoproxil fumarate (TDF). Other antiretroviral products may contain a different prodrug called tenofovir alafenamide (TAF). TDF and TAF are associated with distinct pharmacological properties and are documented to have different safety profiles.

Q: Is Viread available as a generic drug?

A: Formulations containing the active ingredient, tenofovir disoproxil fumarate, are available from various manufacturers in generic form, following the expiration of patent protection for the brand-name drug.

Q: Is it okay to drink alcohol while taking Viread?

A: Official drug information does not contain a specific statement regarding the consumption of alcohol. However, a serious warning associated with the drug class is the risk of severe liver issues, known as Severe Hepatomegaly with Steatosis, which highlights the need for caution regarding liver health.

Q: What if I vomit shortly after taking a dose of Viread?

A: Patient information guidelines state that if vomiting occurs within one hour of taking the dose, instructions suggest that an additional tablet be taken. If vomiting occurs a second time, guidelines describe that a third tablet is not required.

Q: Can Viread be stopped suddenly?

A: For patients co-infected with the Hepatitis B Virus (HBV), abrupt discontinuation of the medication is associated with a risk of severe acute exacerbations of hepatitis B. Because of this risk, patients must undergo close clinical and laboratory monitoring for several months if the drug is stopped.

Q: Do food or dietary changes affect how Viread works?

A: Beyond the specific direction to take the oral powder with food to ensure proper absorption, no significant impacts of general food or dietary changes on the drug’s mechanism of action are listed in official documents.

Q: Is there a maximum dose of Viread mentioned in regulatory documents?

A: The official dosage and administration sections in regulatory documents specify that the adult and pediatric dosing regimens are calculated up to a maximum daily dose of 300 mg of tenofovir disoproxil fumarate.

Q: How is the safety of Viread tracked after it is approved?

A: The safety of the medication is monitored both through controlled clinical trials and through post-marketing surveillance. This surveillance is a system that involves the continuous reporting and tracking of adverse events that occur after the product is released to the public.

Q: What patient groups are generally not recommended to use Viread?

A: The medicine is generally not recommended for use in any patient diagnosed with severe renal impairment, which is defined by a creatinine clearance below 30 mL/min. It is also not recommended for pediatric patients who have existing kidney issues.

Q: Does Viread affect fertility?

A: According to official nonclinical toxicology reports, studies conducted in animals did not reveal evidence of impaired fertility at the exposures tested in those studies.

Q: Are common allergies a concern when starting Viread?

A: Official documents list a contraindication for the drug, meaning it must not be used, in patients who have a known hypersensitivity (a type of severe allergic reaction) to the active substance or any of its inactive ingredients.

Q: Does official information mention any effect of Viread on mental clarity or mood?

A: Official adverse reaction reports list both Depression and Anxiety in some adult clinical trials. Additionally, symptoms like confusion are listed as potential indicators of more serious complications, such as severe kidney impairment or Immune Reconstitution Inflammatory Syndrome (IRIS).

How should Viread be stored and disposed of?

How to Store and Dispose of Viread (Tenofovir Disoproxil Fumarate)

Viread tablets and oral powder must be stored under specific, mandated conditions to maintain product stability and must be disposed of according to strict regulatory guidelines.

Storage Requirements

Viread must be stored at controlled room temperature, specifically 25°C (77°F). Temporary excursions outside this range are permitted, allowing temperatures between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original container, which should be maintained tightly closed to provide protection from moisture; the desiccant must not be removed. For safety, the product must be stored out of the reach and sight of children, supported by the container's child-resistant closure.

Disposal Instructions

Unused or expired Viread should not be disposed of via household waste or poured into wastewater. Disposal must be conducted in accordance with local requirements for medicinal products, typically utilizing a designated pharmaceutical take-back program.

Viread